8,998 Shares in Royalty Pharma plc (NASDAQ:RPRX) Purchased by Vontobel Holding Ltd.

Vontobel Holding Ltd. acquired a new stake in Royalty Pharma plc (NASDAQ:RPRX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 8,998 shares of the biopharmaceutical company’s stock, valued at approximately $230,000.

Other institutional investors also recently bought and sold shares of the company. Brooklyn Investment Group grew its holdings in Royalty Pharma by 1,006.9% in the fourth quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 876 shares during the period. Blue Trust Inc. lifted its position in shares of Royalty Pharma by 362.7% in the third quarter. Blue Trust Inc. now owns 1,203 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 943 shares in the last quarter. Fifth Third Bancorp lifted its position in shares of Royalty Pharma by 187.1% in the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 997 shares in the last quarter. Spire Wealth Management lifted its position in shares of Royalty Pharma by 377.6% in the fourth quarter. Spire Wealth Management now owns 2,149 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 1,699 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Royalty Pharma in the third quarter valued at approximately $61,000. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Stock Performance

Shares of Royalty Pharma stock opened at $33.42 on Friday. Royalty Pharma plc has a one year low of $24.05 and a one year high of $33.69. The company has a market cap of $19.69 billion, a price-to-earnings ratio of 23.05, a PEG ratio of 2.26 and a beta of 0.49. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The business’s 50 day moving average price is $29.18 and its 200 day moving average price is $27.93.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, research analysts predict that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 21st will be given a $0.22 dividend. The ex-dividend date of this dividend is Friday, February 21st. This represents a $0.88 dividend on an annualized basis and a yield of 2.63%. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s payout ratio is currently 57.93%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, November 5th. TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. Finally, Citigroup decreased their target price on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $41.60.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.